【瞩目】东阳光药入局15亿注射剂

米内网
Jun 18, 2025

精彩内容近日,CDE官网显示,东阳光药的德谷门冬双胰岛素注射液以新药3.3类提交NDA获受理,冲刺国产第2家。米内网数据显示,2024年中国三大终端六大市场(统计范围详见本文末)胰岛素及其类似药销售额超过180亿元,在TOP10集团中,东阳光药位列第八。德谷门冬双胰岛素注射液是由德谷胰岛素70%与门冬胰岛素30%组成的复方制剂,主要用于治疗成人2型糖尿病。该药已被纳入国家医保乙类目录,目前仅...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10